NVS (NVS) Stock Price & Analysis
NVS (NVS) rose 1.84% to USD 149.12 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
NVS last closed at USD 146.42; the session ranged USD 147.05–149.71 on volume of 2,293,792 shares. Market capitalization is $284.53B, with a 52-week range of USD 112.34–170.46 (NYQ). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 149.12 |
|---|---|
| Change | ▲ 1.84% (up) |
| Previous Close | USD 146.42 |
| Open | USD 147.19 |
| Day Range | USD 147.05 – 149.71 |
| 52-Week Range | USD 112.34 – 170.46 |
| Volume | 2,293,792 shares |
| Market Cap | $284.53B |
| Exchange | NYQ |
Technical Analysis (NVS)
Nexqual's technical model rates NVS "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.88 (neutral) |
| vs SMA50 | Below (USD 149.24) |
| MACD | -0.42 (negative) |
Analyst Ratings (NVS)
Wall Street analysts rate NVS "Hold" based on 10 analysts, with a mean price target of USD 153.87 (range USD 123–180), per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 153.87 |
| High Target | USD 180 |
| Low Target | USD 123 |
| Buy / Hold / Sell | 5 / 5 / 2 |
Earnings (NVS)
| Next Earnings Date | 2026-07-21 |
|---|---|
| EPS Estimate | USD 2.11 |
| Revenue Estimate | $14.23B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.99 vs est 2.07 ▼ miss |
| 2025-12-31 | USD 2.03 vs est 2 ▲ beat |
| 2025-09-30 | USD 2.25 vs est 2.31 ▼ miss |
| 2025-06-30 | USD 2.42 vs est 2.37 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (NVS)
| Total Revenue | $56.58B |
|---|---|
| Revenue Growth (YoY) | -0.70% |
| Gross Margin | +75.55% |
| Operating Margin | +30.48% |
| Profit Margin | +23.92% |
| ROE | +34.93% |
| Debt / Equity | 120.73 |
| Current Ratio | 0.85 |
| Total Cash | $6.89B |
| Total Debt | $47.00B |
| Free Cash Flow | $12.02B |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (NVS)
Nexqual rates NVS's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 76%, operating 30% |
| Balance Sheet | Weak — $6.89B cash vs $47.0B debt |
| Cash Flow | Strong — FCF $12.0B, 21% margin |
| Efficiency | Strong — ROE 35%, ROA 10.5% |
Ownership (NVS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +7.70% |
| Shares Outstanding | 1.91B |
| Float | 1.81B |
| Short % of Float | +0.23% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Leadership (NVS)
NVS is led by Vasant Narasimhan (age 49), Chief Executive Officer, per Nexqual as of June 9, 2026 at 23:51 UTC.
| Chief Executive Officer | Vasant Narasimhan (age 49) |
|---|---|
| President of US | Victor Bulto (age 47) |
| President of International | Patrick Horber (age 55) |
| Chief Financial Officer | Mukul Mehta (age 52) |
| President of Operations | Steffen Lang (age 58) |
Major Backers & Investors (NVS)
Notable institutional backers of NVS include Fisher Asset Management, LLC, Dodge & Cox Inc., Morgan Stanley, according to Nexqual as of June 9, 2026 at 23:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fisher Asset Management, LLC | 0.68% |
| Dodge & Cox Inc. | 0.59% |
| Morgan Stanley | 0.42% |
| Primecap Management Company | 0.37% |
| LOOMIS SAYLES & CO L P | 0.34% |
| Goldman Sachs | 0.32% |
| Bank of America Corporation | 0.24% |
| Franklin Resources, Inc. | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Dimensional Fund Advisors | 0.44% |
| Vanguard Group | 0.32% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNY | Sanofi | USD 44.73 | ▼ 0.64% |
| GSK | GSK plc | USD 51.25 | ▼ 0.52% |
| AZN | AstraZeneca PLC | USD 183.43 | ▼ 1.36% |
| RHHBY | Roche Holding Ltd | USD 50.01 | ▼ 2.86% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.